AR127585A1 - Vacuna de arn de virus sincicial respiratorio - Google Patents

Vacuna de arn de virus sincicial respiratorio

Info

Publication number
AR127585A1
AR127585A1 ARP220103037A ARP220103037A AR127585A1 AR 127585 A1 AR127585 A1 AR 127585A1 AR P220103037 A ARP220103037 A AR P220103037A AR P220103037 A ARP220103037 A AR P220103037A AR 127585 A1 AR127585 A1 AR 127585A1
Authority
AR
Argentina
Prior art keywords
rsv
vaccine
virus rna
rna vaccine
eliciting
Prior art date
Application number
ARP220103037A
Other languages
English (en)
Inventor
Danilo Casimiro
Hardip Rajeshbhai Gopani
Joshua Dinapoli
Linong Zhang
Mark Parrington
Rebecca Goldman
Sudha Chivukula
William Scott Gallichan
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of AR127585A1 publication Critical patent/AR127585A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente divulgación proporciona una vacuna contra el virus respiratorio sincitial (VRS) que comprende un ARN mensajero (ARNm) que comprende un marco de lectura abierto (ORF) que codifica un antígeno proteico F del VRS, y métodos para provocar una respuesta inmunitaria mediante la administración de dicha vacuna. Reivindicación 35: Un método para provocar una respuesta inmunitaria contra el VRS o para proteger a un sujeto contra la infección por el VRS, que comprende la administración de la vacuna contra el VRS de una cualquiera de las reivindicaciones 1 a 34 a un sujeto.
ARP220103037A 2021-11-05 2022-11-04 Vacuna de arn de virus sincicial respiratorio AR127585A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163276233P 2021-11-05 2021-11-05
EP22315065 2022-03-16

Publications (1)

Publication Number Publication Date
AR127585A1 true AR127585A1 (es) 2024-02-07

Family

ID=84357817

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220103037A AR127585A1 (es) 2021-11-05 2022-11-04 Vacuna de arn de virus sincicial respiratorio

Country Status (7)

Country Link
US (1) US20230302112A1 (es)
AR (1) AR127585A1 (es)
AU (1) AU2022382104A1 (es)
CA (1) CA3236924A1 (es)
IL (1) IL312334A (es)
TW (1) TW202346593A (es)
WO (1) WO2023079507A1 (es)

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4401796A (en) 1981-04-30 1983-08-30 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
ATE420171T1 (de) 1994-07-15 2009-01-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
AU760549B2 (en) 1998-04-03 2003-05-15 University Of Iowa Research Foundation, The Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
AU2005245956B2 (en) 2004-05-18 2011-05-19 Alphavax, Inc. TC-83-derived alphavirus vectors, particles and methods
WO2011005799A2 (en) 2009-07-06 2011-01-13 Novartis Ag Self replicating rna molecules and uses thereof
NZ600616A (en) 2009-12-01 2014-11-28 Shire Human Genetic Therapies Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
WO2012075040A2 (en) 2010-11-30 2012-06-07 Shire Human Genetic Therapies, Inc. mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
KR102128248B1 (ko) 2011-06-08 2020-07-01 샤이어 휴먼 지네틱 테라피즈 인크. Mrna 전달을 위한 지질 나노입자 조성물 및 방법
KR102272498B1 (ko) 2011-10-27 2021-07-06 메사추세츠 인스티튜트 오브 테크놀로지 약물 캡슐화 마이크로스피어를 형성할 수 있는, ｎ-말단 상에 관능화된 아미노산 유도체
EA201492055A1 (ru) 2012-06-08 2015-11-30 Шир Хьюман Дженетик Терапис, Инк. ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ
US9738689B2 (en) * 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
BR112015022505A2 (pt) 2013-03-14 2017-10-24 Shire Human Genetic Therapies avaliação quantitativa para eficiência do cap de rna mensageiro
EP3757570B1 (en) 2013-03-15 2023-10-11 Translate Bio, Inc. Synergistic enhancement of the delivery of nucleic acids via blended formulations
SG10201801428RA (en) 2013-08-21 2018-03-28 Curevac Ag Method for increasing expression of rna-encoded proteins
ES2806575T3 (es) 2013-11-01 2021-02-18 Curevac Ag ARN modificado con propiedades inmunoestimuladoras disminuidas
JP6704850B2 (ja) 2013-12-30 2020-06-03 キュアバック アーゲー 人工核酸分子
WO2015101415A1 (en) 2013-12-30 2015-07-09 Curevac Gmbh Artificial nucleic acid molecules
JP6782171B2 (ja) 2014-07-02 2020-11-11 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド メッセンジャーｒｎａのカプセル化
PL3708668T3 (pl) 2014-12-12 2022-12-05 Curevac Ag Sztuczne cząsteczki kwasu nukleinowego dla poprawy ekspresji białka
WO2016174271A1 (en) 2015-04-30 2016-11-03 Curevac Ag Immobilized poly(n)polymerase
AU2016278970B2 (en) 2015-06-19 2020-10-29 Massachusetts Institute Of Technology Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell
MA47016A (fr) * 2015-10-22 2018-08-29 Modernatx Inc Vaccins contre les virus respiratoires
WO2017162265A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Trans-replicating rna
IL266501B2 (en) 2016-11-10 2024-06-01 Translate Bio Inc An improved ICE-based lipid nanoparticle formulation for delivery of mRNA
EP3538073A1 (en) 2016-11-10 2019-09-18 Translate Bio, Inc. Improved process of preparing mrna-loaded lipid nanoparticles
EP3595713A4 (en) * 2017-03-15 2021-01-13 ModernaTX, Inc. RESPIRATORY SYNCYTIAL VIRUS VACCINE
EP3746090A4 (en) * 2018-01-29 2021-11-17 ModernaTX, Inc. RSV RNA Vaccines
CN112512567A (zh) 2018-04-03 2021-03-16 赛诺菲 抗原性呼吸道合胞病毒多肽
CA3119071A1 (en) * 2018-11-09 2020-05-14 Arbutus Biopharma Corporation Lipid nanoparticle formulations
JP2022542562A (ja) 2019-07-23 2022-10-05 トランスレイト バイオ， インコーポレイテッド ｍＲＮＡ担持脂質ナノ粒子の安定性組成物および作製のプロセス

Also Published As

Publication number Publication date
TW202346593A (zh) 2023-12-01
CA3236924A1 (en) 2023-05-11
AU2022382104A1 (en) 2024-06-20
IL312334A (en) 2024-06-01
US20230302112A1 (en) 2023-09-28
WO2023079507A1 (en) 2023-05-11

Similar Documents

Publication Publication Date Title
CO2018005229A2 (es) Vacuna de virus sincitial respiratorio
CO2017011245A2 (es) Conjugados proteína-polisacárido de estreptococo grupo b, métodos para producir conjugados, composiciones inmunógenas que comprenden conjugados y sus usos
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
PH12021550479A1 (en) Dengue vaccine unit dose and administration thereof
ECSP10010723A (es) Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso
AR108829A1 (es) Vacuna contra virus de bronquitis infecciosa
EA201171032A1 (ru) Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
MX2019003682A (es) Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas.
EA201891124A3 (ru) Новые мукозные адъюванты и системы доставки
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
CO2022012272A2 (es) Vacunas contra el coronavirus y métodos de uso
PE20170429A1 (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9
BR112023021654A2 (pt) Vacina contra vírus
BR112018015912A2 (pt) vírus da vacina da síndrome respiratória e reprodutiva porcina
CL2020002876A1 (es) Vacuna contra la bronquitis infecciosa (divisional de la solicitud no. 201803420)
AR127585A1 (es) Vacuna de arn de virus sincicial respiratorio
MX2022012527A (es) Vacunas, adjuvantes, y metodos para generar una respuesta inmunitaria.
CL2023002187A1 (es) Virus para vacuna contra el síndrome respiratorio y reproductivo porcino
BR112022007474A2 (pt) Vacina de partículas semelhantes a vírus chikungunya e métodos de uso da mesma
MX2022001742A (es) Metodos para prevenir el dengue y la hepatitis a.
CA3242439A1 (en) Lyme disease rna vaccine
BR112022020100A2 (pt) Vacina inativada contra vírus sars-cov-2
Romagosa et al. Influenza virus transmission rates in vaccinated and non-vaccinated pig populations
PH12020550948A1 (en) Vaccines against hendra and nipah virus infection
AR122539A1 (es) UNA VACUNA CONTRA EL SARS-CoV-2